- Home
- MLSS vs KPTI Comparison
MLSS vs KPTI Comparison
Compare MLSS & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLSS
- KPTI
- Stock Information
- Founded
- MLSS 1989
- KPTI 2008
- Country
- MLSS United States
- KPTI United States
- Employees
- MLSS N/A
- KPTI N/A
- Industry
- MLSS Industrial Specialties
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- MLSS Health Care
- KPTI Health Care
- Exchange
- MLSS Nasdaq
- KPTI Nasdaq
- Market Cap
- MLSS 42.4M
- KPTI 44.5M
- IPO Year
- MLSS 1995
- KPTI 2013
- Fundamental
- Price
- MLSS $0.64
- KPTI $3.94
- Analyst Decision
- MLSS Buy
- KPTI Buy
- Analyst Count
- MLSS 1
- KPTI 7
- Target Price
- MLSS $1.25
- KPTI $48.50
- AVG Volume (30 Days)
- MLSS 942.3K
- KPTI 148.2K
- Earning Date
- MLSS 08-22-2025
- KPTI 08-11-2025
- Dividend Yield
- MLSS N/A
- KPTI N/A
- EPS Growth
- MLSS N/A
- KPTI N/A
- EPS
- MLSS N/A
- KPTI N/A
- Revenue
- MLSS $8,613,503.00
- KPTI $142,126,000.00
- Revenue This Year
- MLSS $25.28
- KPTI $2.18
- Revenue Next Year
- MLSS $20.75
- KPTI $11.28
- P/E Ratio
- MLSS N/A
- KPTI N/A
- Revenue Growth
- MLSS N/A
- KPTI 1.19
- 52 Week Low
- MLSS $0.38
- KPTI $3.51
- 52 Week High
- MLSS $1.39
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- MLSS 53.53
- KPTI 44.36
- Support Level
- MLSS $0.50
- KPTI $3.81
- Resistance Level
- MLSS $0.68
- KPTI $4.35
- Average True Range (ATR)
- MLSS 0.07
- KPTI 0.38
- MACD
- MLSS 0.02
- KPTI -0.01
- Stochastic Oscillator
- MLSS 86.50
- KPTI 19.17
About MLSS Milestone Scientific Inc.
Milestone Scientific Inc is a biomedical technology company. The company is engaged in pioneering proprietary, technological systems and solutions for the medical and dental markets. The company develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetics. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. The Company conducts its business through two reportable segments: Dental and Medical.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.